Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Latest Press Releases

Latest Press Releases

Girl with post Kala Azar Dermal Leishmaniasis, a recurrent but non-fatal form of Kala Azar that affects 5-10 per cent of patients between six months to three years after cure. Photograph by Matthew Smeal
Press release
Press release |
07 June 2017
Research and development

US Congressional Committee advances legislation that fails to fix FDA PRV program for neglected diseases

Gloria Chipasula, 11 years old MSF's HIV and TB positive patient stands in in the middle of the road (green dressed) as she plays with her young relatives and village's friends. Photograph by Luca Sola
Press release
Press release |
06 June 2017
HIV/AIDS
India

Press note: Child-friendly formulation of WHO-recommended HIV treatment now approved by the CDSCO

5 min
FTA Protest Photograph by Siddharth Singh
Press release
Press release |
29 May 2017
Intellectual property and trade
SwitzerlandIndia

MSF response on the India-EFTA free trade agreement negotiations in Liechtenstein this week

4 min
Civil society demonstration against IP provisions in RCEP that can block access to affordable medicines. Outside Ministry of Commerce, Udyog Bhawan, New Delhi Photograph by Siddharth Singh
Press release
Press release |
08 May 2017
Intellectual property and trade
IndiaPhilippines

MSF response on RCEP negotiations in the Philippines

4 min
In New York, on Word Pneumonia Day 2015 (Nov 12), MSF volunteers attempted to deliver more than $17 million of fake cash - the equivalent of one day of profits from the pneumonia vaccines for Pfizer globally -  to Pfizer's CEO Ian Read. The same day, MSF launched a global petition to ask Pfizer and GlaxoSmithKline (GSK) to reduce the price of the pneumococcal vaccine to $5 dollars per child (for all three doses) in developing countries. Credit: Edwin Torres. Photograph by Edwin Torres
Press release
Press release |
27 April 2017
Vaccines

Investors join MSF in calling Pfizer to reduce the price of vaccine against top childhood killer

A coolbox full of vaccines for the massive MSF multi antigen campaign in Bangassou sub-prefecture, Mbomou prefecture, CAR. Photograph by Sandra Smiley Photograph by Sandra Smiley
Press release
Press release |
26 April 2017
Vaccines

Study: Replacing existing vaccines with heat-stable versions saves money, protects more mothers and children from deadly diseases

5 min
Vials of PCV13, a vaccine that protects children against pneumonia and meningitis. At 9 Euros a dose (three doses are necessary for the vaccine to be effective) PCV13 is currently priced at a rate much higher than most people in Central African Republic can afford. Photograph by Sandra Smiley Photograph by Sandra Smiley
Press release
Press release |
25 April 2017

US Department of Defense announces decision to give pharmaceutical corporation exclusive rights on taxpayer-funded Zika vaccine

First set of free Hepatitis C medicines Sofosbuvir and Daclatasvir provided by Delhi Govt. run GB Pant hospital. Photograph by Garvit Nangia Photograph by Garvit Nangia
Press release
Press release |
31 March 2017
Intellectual property and trade
Brazil

Scale up of hepatitis C treatment possible as Brazil rejects patent on key drug

5 min
  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury